Biomarker of Lung Disease in African Americans

项目摘要/摘要 慢性阻塞性肺病(COPD)是美国第三大死因。 COPD主要发生在吸烟者中，目前尚不清楚为什么只有一小部分吸烟者(~20%-40%)发病 慢性气流受限或远端空间破坏(肺气肿)。鉴定分子图谱的来源 可能进展的现任或既往吸烟者是了解糖尿病发病机制的关键一步 慢性阻塞性肺病和肺气肿。 这项研究将利用大型NIH- 支持的队列(COPDgene、SPIROMICS和MESA-LONG)具有大量特征良好的 非裔美国人患有或有患慢性阻塞性肺病的风险。因为受试者已经储存了血浆 经过7-10年的广泛临床、生理和成像，我们可以非常经济高效地应用 蛋白质组学方法。此外，因为队列拥有其他有价值的Omics数据，所以我们可以集成 蛋白质组学发现与全基因组测序和其他高级分子研究，如基因组学。 这一知识可能有助于开发新的诊断测试和治疗方法，用于早期预防和治疗 并将确定任何针对非裔美国人吸烟相关肺部疾病的标志物。

PROJECT SUMMARY/ABSTRACT Chronic obstructive pulmonary disease (COPD) is the 3rd leading cause of death in the US1,2. Although COPD occurs predominantly in smokers, it is unknown why only a minority of smokers (~20-40%) develops chronic airflow limitation or destruction of distal airspaces (emphysema). Identification molecular profiles from current or former smokers who are likely to progress is a crucial step in understanding the pathogenesis of COPD and emphysema. There are very few publications that describe COPD biomarkers in large, well phenotyped cohorts that include a significant number of African Americans. This study will leverage large NIH- supported cohorts (COPDGene, SPIROMICS, and MESA-Lung) that have large number of well-characterized African Americans subjects with or at risk for COPD. Since the subjects have stored plasma and have been followed for 7-10 years with extensive clinical, physiologic, and imaging, we can very cost-effectively apply a proteomic approach. Furthermore, because the cohorts have other valuable Omics data, we can integrate the proteomic findings with whole genome sequencing and other advanced molecular studies such as genomics. This knowledge may help develop novel diagnostic tests and therapies for early prevention and treatment of COPD and will identify any markers that are specific to smoking-related lung disease in African Americans.